Repare Therapeutics shareholders approve acquisition by XenoTherapeutics

Repare Therapeutics (RPTX) announced that its shareholders have approved the acquisition of all of the issued and outstanding common shares of the company by XenoTherapeutics and Xeno Acquisition Corp. by way of a statutory plan of arrangement at the special meeting of Shareholders held on January 16. The arrangement is subject to the approval of the Superior Court of Quebec and other customary closing conditions. The Court hearing for the final order to approve the Arrangement is expected to take place on January 23, and, assuming receipt of the approval of the Court and satisfaction of other customary conditions to closing, the completion of the arrangement is expected to occur on or about January 28.